Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB

The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed acute lymphoblastic leukemia (ALL) patients. However, a limited efficacy of bortezomib alone has been reported. A terminal pro-apoptotic endoplasmic reticulum (ER) stress/unfolded protein response (UPR)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Buontempo, Francesca, Orsini, Ester, Lonetti, Annalisa, Cappellini, Alessandra, Chiarini, Francesca, Evangelisti, Camilla, Evangelisti, Cecilia, Melchionda, Fraia, Pession, Andrea, Bertaina, Alice, Locatelli, Franco, Bertacchini, Jessika, Neri, Luca Maria, McCubrey, James A., Martelli, Alberto Maria
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4811463/
https://ncbi.nlm.nih.gov/pubmed/26593250
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados